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ABSTRACT
Paclitaxel is a promising drug in the treatment of different solid tumors. It exhibits nonlinear pharmacokinetics, 
particularly when administered as a constant rate infusion for shorter duration (e.g., 3 h). Because of the 
nonlinearity, relatively small changes in dose may lead to large changes in peak plasma concentration and 
total drug exposure. The study was conducted to evaluate the pharmacokinetics of different doses of paclitaxel 
administered intravenously as an infusion. A prospective study was conducted in 23 cancer patients aged 
between 28 and 74 years, treated with paclitaxel (130, 200, 230, and 260 mg/m2) over 3 h as constant rate 
infusion. Plasma samples were collected from all patients at 0, 1, and 3 h and for five patients at 5 and 13 h and 
paclitaxel concentrations were determined using high‑performance liquid chromatography method. The overall 
mean clearance was found to be 47.5847 ± 142.028 l/h; the mean volume of distribution was 142.028 ± 73.438 l; 
mean elimination rate constant was 0.336 ± 0.002/h; mean half‑life was 2.086 ± 0.009 h; mean area under the 
curve (AUC) was 5.5917 ± 2.707 mg/ml*h; and the mean of mean residence time was 2.980 ± 0.0131 h. Paclitaxel 
showed nonlinear kinetics and the pharmacokinetic parameters calculated were similar to those quoted in the 
literature. The peak plasma concentration at 130 mg dose level was 2 μ/ml, but an increase in dose was not 
associated with proportional increase in plasma concentration. No significant difference was found between 
pharmacokinetic parameters such as clearance, volume of distribution, and AUC at different dose levels.
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Paclitaxel is a potent anticancer drug.[2,3] Paclitaxel, with 
its unique mechanism of action as an inducer of tubulin 
polymerization, has demonstrated impressive clinical 
antitumor activity in patients with breast, lung, head, neck, 
and advanced platinum‑refractory ovarian carcinoma. It 
appears to be one of the most promising agents for the 
first‑ or second‑line chemotherapy of solid tumors.[4]
Paclitaxel exhibits nonlinear pharmacokinetics, particularly 
when the drug is administered over shorter periods of 
infusion (3 h). Both saturable distribution and elimination 
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contribute to the nonlinear disposition of paclitaxel. 
Because of the nonlinearity of its pharmacokinetics, 
relatively small changes in dose may lead to large changes 
in peak plasma concentrations and total drug exposure. 
Following intravenous administration, paclitaxel is widely 
distributed into body fluids and tissues. It has a large 
volume of distribution that appears to be affected by dose 
and duration of infusion.[5‑9]
Paclitaxel is extensively metabolized in the liver. Metabolism 
to its major metabolite, 6a‑hydroxypaclitaxel, is mediated by 
cytochrome P‑450 isoenzyme CYP2C8, while metabolism 
to two of its minor metabolites, 3'‑p‑hydroxypaclitaxel and 
6a, 3'‑p‑dihydroxypaclitaxel, is catalyzed by CYP3A4.35. 
Paclitaxel and its metabolites are excreted principally in 
the feces via biliary elimination. Both a reduction in the 
clearance and an overproportional increase in peak plasma 
concentration (Cmax) of paclitaxel are observed with 
increasing dosages indicative that both drug elimination 
and distribution were affected.[10]
Safety and efficacy of paclitaxel have been studied 
extensively.[11] However, its complete pharmacokinetic 
profile in humans has not yet been fully understood. With 
this in background, pharmacokinetics of paclitaxel has 
been studied with the objectives of optimizing the dose 
to achieve desired plateau plasma‑drug concentration, to 
maximize response and reduce toxicity of drug, and to 
learn what factors affect plasma concentrations in the 
study population.
MATERIALS AND METHODS
A prospective study was conducted between September 
2008 and March 2009, in the medical oncology wards of 
a 1675‑bedded tertiary care teaching hospital in South 
India, with the approval of the Institutional Ethics 
Committee (IEC/08/SEP/68/33) and the consent of 
the study participants. Patients above 18 years of age, 
with histologically confirmed malignancy and treated with 
paclitaxel were enrolled in this study.
A detailed data of all the patients were collected which 
included demographics (age, sex, weight, and height) 
disease status, smoking habits, alcoholic consumption, 
family history, co morbidities (Cardiovascular, renal, 
and hepatic diseases), and medications taken along with 
paclitaxel.
The patients were administered paclitaxel at the doses of 
130, 200, 230, and 260 mg/m2 intravenously as constant 
rate infusion over 3 h. Vials containing 6 mg/ml of 
paclitaxel supplied by Feron life sciences (Pacliron), Intas 
biopharmaceuticals (Cytax), and Macmoham Pharma Ltd. 
(Amtax) were used for this study. After 3 h of paclitaxel 
infusion, patients were administered intravenous saline for 
3 h. The saline was stopped, and patients were given either 
one or two of the following drugs cisplatin, carboplatin, 
and 5‑fluorouracil. The patients were also treated with 
dexamethasone 8 mg intravenous, ranitidine 50 mg 
intravenous, diphenhydramine 50 mg intramuscular, and 
palanosetran 0.25 mg in 100 ml of saline over 30 min 
before starting paclitaxel therapy.
Heparinized blood samples were collected from the 
patients before starting paclitaxel infusion (0 h) and at the 
time intervals of 1 and 3 h for all patients; 5 and 13 h for 
five patients and were stored at −80°C. The extraction of 
paclitaxel from the biological matrix was carried out by 
using protein precipitation method.
The plasma concentrations of paclitaxel at various time 
intervals were determined using high‑performance liquid 
chromatography (HPLC), and pharmacokinetic parameters 
of paclitaxel at different dose levels were evaluated.
Estimation of plasma concentrations of paclitaxel 
by HPLC
Paclitaxel estimations by HPLC were conducted at 
Dr. T M A Pai Bioavailability Center, Manipal College 
of Pharmaceutical Sciences, Manipal. The estimations 
were carried out by adapting a validated method stated 
in “Analytical Methods Validation: Bioavailability, 
Bioequivalence and Pharmacokinetic Studies,”[12] with 
minor modification as stated in the study done by Alex 
Sparreboom.[13]
Materials
1.  Paclitaxel:  Natco Pharma Ltd. (standard)
2.  Celecoxib: Dr. Reddy’s Laboratories (Internal standard)
3.  Acetonitrile (HPLC grade): E‑Merck (India) Limited, 
Mumbai.
4.  Methanol (HPLC grade): E‑Merck (India) Limited, 
Mumbai.
5.  Glacial acetic acid (GR grade): E‑Merck (India) Limited, 
Mumbai.
6.  Eppandorff tubes (2 ml): Tarsons Products Pvt. Ltd., 
Kolkata.
7.  Centrifuge tubes (15 ml): Tarsons Products Pvt. Ltd., 
Kolkata.
8.  Micro tips (1 ml, 0.2 ml, and10 μl): Tarsons Products 
Pvt. Ltd., KolkataJanardhan, et al.: Pharmacokinetics of paclitaxel
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Equipment
The  HPLC  system  with  LC‑2010HT  HPLC 
Spectrophotometer detector (Shimadzu, Kyoto, Japan). 
Synergi 4u Fusion‑RP 80A, 5 μm, 250 × 4.6 mm, SS C18 
column (Denali) was used for the analysis.
Chromatographic conditions
Mobile phase  :   Acetonitrile: Acetate buffer (4.5) 
mixture (60:40)
Flow rate  : 1 ml/min
Pressure  : 100 kg.f/cm2
Injection volume  :  50 μl
Column temperature : Room temperature
UV detection at  : 230 nm
Preparation of mobile phase
Mobile phase consisting of acetonitrile: Acetate buffer 4.5 
(60:40) was prepared by addition of specified quantities and 
mixed thoroughly. Mobile phase was degassed and used for 
the HPLC analysis; 1.0 ml/min flow rate was maintained 
throughout the analysis. The eluent was monitored using 
UV detector set at 230 nm.
Preparation of standard solution
Stock solutions of 1 mg/ml of paclitaxel were 
prepared in double distilled water. These solutions 
were further diluted with double distilled water to produce 
working stock solutions of 100; 10 μg/ml. All solutions 
were stored at −4°C.
Preparation of ammonium acetate buffer (pH 4.5)
About 1.44 g of ammonium acetate was weighed accurately 
and dissolved in 1000 ml of Millipore water. The pH was 
adjusted using glacial acetic acid.
Extraction procedure
The extraction of paclitaxel from the biological matrix 
was carried out by using protein precipitation method. 
This method was carried out by using precipitating 
agent acetonitrile. One hundred microliters of paclitaxel 
containing human plasma sample was taken into 1.5 ml 
of centrifuge tubes and 10 μl of 100 μg/ml celecoxib was 
added as internal standard and vertexed for 5 min, then it 
was centrifuged at 10,000 rpm for 10 min, and the clear 
supernatant (around 50 μl each) was transferred into HPLC 
vials and was subjected to HPLC analysis.
Preparation of calibration curve of paclitaxel in 
human plasma
Plasma used for plotting the standard graph was obtained 
from healthy volunteers. Different concentrations 
(50,100, 200, 500, 1000, 2500, 5000, and 10,000 ng/ml) 
of paclitaxel along with a constant concentration of 
internal standard (100 μg/ml) in plasma were prepared for 
calibration curve. The samples were treated as above for 
extraction. The extracted sample (50 μl) was injected and 
eluted with mobile phase. Column solvents were degassed 
before use. The peak ratios of responses of standard drug 
(paclitaxel) and internal standard (celecoxib 100 μg) were 
noted down. The peak ratios of responses multiplied by 
1000, obtained at different concentrations of the drug, 
were plotted against the concentrations of drug. The slope 
of the plot determined by the method of least square 
regression analysis was used to calculate the paclitaxel 
concentration in the unknown sample [Table 1]. The 
linearity was found to be in the range 50–10,000 ng/ml 
of paclitaxel in plasma, with a mean regression correlation 
coefficient of (r2 = 0.9996) in plasma matrix [Figure 1]. 
The lowest limit of quantification was established 
at 50 ng/ml and the upper limit of quantification at 
10,000 ng/ml, both the mean percentage deviation 
and the between run precision were less than 5%. The 
retention times of paclitaxel and celecoxib were 6.7 and 
10.6 min, respectively.
Analysis of the blood samples
Blood samples were run along with quality controls, and 
concentrations were determined from calibration curve. 
The pharmacokinetic parameters were estimated with 
manual calculators using the following equations.[8]
1.  Total clearance:
  Clearance = dosing rate/Css (peak plasma concentration 
at steady state); units = l/h
2.  Volume of distribution:
Table 1: Linearity of paclitaxel and internal standard at 
various concentrations
Drug concentrations 
(ng/ml)
Drug 
response
Internal 
standard
Peak 
ratio
50 3,923 235,089 0.01
100 8,874 229,044 0.04
200 23,504 231,579 0.10
500 43,517 247,732 0.18
1,000 95,886 226,548 0.42
2,500 216,643 236,578 0.92
5,000 435,636 221,545 1.96
10,000 895,955 225,074 3.85Janardhan, et al.: Pharmacokinetics of paclitaxel
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Volume of distribution
=
amount present in the body
Css (peak   plasma concentration at steady state)
units=l
;
3.  Elimination rate constant:
  Elimination rate constant = clearance/volume of 
distribution; units = min−1
4.  Half‑life:
  Half‑life (t½) = 0.693/K; units = hour or min.
5.  Area under curve:
  Area under curve = clearance/volume of distribution; 
units = mg/ml.
6.  Mean residence time (MRT):
  MRT = volume of distribution/clearance; units = h
RESULTS
A total of 23 cancer patients (8 males and 15 females) 
were enrolled in this study. The baseline characteristics 
of the study population are shown in Table 2. The mean 
age of the patients was 47 years (range 28–71 years) 
and the mean body surface area was 1.54 m2 (range 
1.28–1.94 m2). Majority of the patients (n=10; 43.48%) 
had breast cancer.
Estimation of plasma concentration of paclitaxel
The study adopted a validated HPLC assay for the 
determination of the concentration of paclitaxel in plasma. 
The blank, standard, and test chromatograms (plasma) are 
shown in Figures 2 and 3. Paclitaxel was given as a constant 
rate intravenous infusion for 3 h only and then stopped; 
hence peak concentration and steady state were achieved 
at 3 h and subsequently dropped.
Pharmacokinetic parameters
The pharmacokinetic parameters of different doses of 
paclitaxel in the study population are shown in Table 3. The 
overall mean clearance was found to be 47.5847 ± 142.028 l/h; 
the mean volume of distribution was 142.028 ± 73.438 l; 
mean elimination rate constant was 0.336 ± 0.002/hour; 
mean half‑life was 2.086 ± 0.009 h; mean area under the 
curve (AUC) was 5.5917 ± 2.707 mg/ml*h; the mean 
of MRT was 2.980 ± 0.0131 h. The mean values of 
the pharmacokinetic parameters (clearance, volume of 
distribution, elimination rate constant, half‑life, AUC, and 
MRT) for doses of paclitaxel at 130, 230, 200, and 260 mg 
of constant infusion for 3 h were given as in Table 3.
Statistical analysis
The results were statistically analyzed by analysis of 
variance (ANOVA). The age of the patients was correlated 
with mean volume of distribution [Table 4]. The volume 
of distribution decreased with increase in age but was not 
statistically significant (F=0.09; P=0.914). There was a 
significant increase in volume of distribution as body weight 
increased (F=1.103; P=0.351) as shown in Table 5. The 
body surface area (F=0.332; P=0.802 and serum creatinine 
levels (F=0.08; P=0.780) did not have a significant effect 
on mean volume of distribution, and the patients with 
serum creatinine values >1.0 showed an increased volume 
of distribution [Tables 6 and 7]. Clearance was directly 
proportional to volume of distribution (F=1.22; P=1.89) 
but was not statistically significant [Table 8].
Figure 1: Linearity plot of paclitaxel
Table 2: Baseline characteristics of study population
Patient characteristics (n=23) Mean (%) Range
Males/females 8/15 —
Age (years) 47 28–71
Body surface area (m2) 1.54 1.28–1.94
Body weight (kg) 57 40–77
Serum creatinine (mg/dl) 0.85 0.4–1.3
Dose (mg) 205 130–260
Cancer type
Breast
Stomach
Lung
Ovarian
Esophagus
Pancreas
Nasopharyngeal
Cervix
10 (43.47)
3 (13.04)
1 (3.85)
3 (13.04)
1 (3.85)
1 (3.85)
2 (8.7)
2 (8.7)
  Y = aX + b  a = 3.792014e -004  b = 6.046113e-003   R^2 = 0.9996166  
0  1000   2000   3000   4000   5000   6000   700 8000   900 Conc. Ratio  
0.0
0. 2
0.5
0.7
1.0
1.2
1.5
1.7
2.0
2.2
2.5
2.7
3.0
3.2
3.5
3.7
4.0
Response   ratio  Janardhan, et al.: Pharmacokinetics of paclitaxel
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Table 3: Mean values of paclitaxel pharmacokinetic parameters at different doses
Dose 
(mg/m2)
No. of patients 
(N=23)
Mean 
Css (mg)
Mean 
CL (l/h)
Mean 
Vd (l)
Mean 
K (/h)
Mean  
T1/2 (h)
Mean AUC 
(mg/ml.h)
Mean 
MRT (h)
130 5 0.003 8.56 54.84 0.34 2.09 8.52 2.95
200 6 0.002 34.65 103.44 0.34 2.09 6.17 2.99
230 3 0.001 54.73 163.48 0.34 2.09 4.33 2.99
260 9 0.001 69.95 209.04 0.34 2.09 3.99 2.99
Mean 47.58 142.03 0.34 2.09 5.59 2.98
SD 24.52 73.44 0.00 0.00 2.71 0.014
Table 4: Age versus mean volume of distribution
Age (years) (n=23) Mean Vd (l) Standard deviation ANOVA
<40 (n=6) 153 ±81.04 F=0.09
40–60 (n=16) 138 ±75.16 P=0.914
>60 (n=1) 132 ±73.43
Table 5: Weight versus mean volume of distribution
Weight (kg) (n=23) Mean Vd (l) Standard deviation ANOVA
40–50 (n=6) 105 ±47.17 F=1.103
50–60 (n=9) 147 ±99.65 P=0.351*
>60 (n=8) 163 ±48.24
*Significant.
Table 6: Body surface area versus mean volume of 
distribution
Body surface area (m2) 
(N=23)
Mean Vd (l) Standard 
deviation
ANOVA
1.2–1.4 (n=6) 133 ±61.1 F=0.332
>1.4–1.6 (n=8) 129 ±87.9 P=0.802
>1.6–1.8 (n=8) 163 ±75.5
>1.8–2 (n=1) 118 ±73.4
Figure 2: HPLC Chromatograms (a) chromatogram of standards;   
(b) chromatogram of human plasma (healthy volunteers)
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Figure 3: HPLC chromatogram patients’ blood samples at 3 h
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Table 7: Serum creatinine versus mean volume of 
distribution
Serum creatinine 
(mg/dl) (N=23)
Mean Vd (l) Standard 
deviation
ANOVA
<1.2 (n=17) 130 ±71.89 F=0.080
>1.2 (n=6) 173 ±74.64 P=0.780
Table 8: Clearance versus mean volume of distribution
Clearance (Liters/Hour)
(N=23)
Mean Vd (l) Standard 
deviation
ANOVA
<40 (n=10) 76 ±35.00 F=1.22
40–60 (n=4) 125 ±5.04 P=1.89
>60 (n=9) 221 ±29.07
DISCUSSION
Paclitaxel is a promising drug in the treatment of different 
solid tumors. In our hospital, 3‑h infusion is used at four 
dose levels 130, 200, 230, and 260 mg. This study was 
undertaken with the aim of assessing pharmacokinetic 
parameters in constant rate intravenous infusion model 
at different dose levels. Several studies have shown that Janardhan, et al.: Pharmacokinetics of paclitaxel
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Peripheral neuropathy was the only adverse effect reported 
by most of the patients in this study. Other side effects such 
as hypotension, congestive heart failure, and bradycardia 
were not reported. Having assessed the pharmacokinetic 
parameters of paclitaxel, we can optimize the dose to 
achieve the desired plasma drug concentration to maximize 
the response and reduce the toxicity of the drug.
The pharmacokinetics of paclitaxel (Pacliron) in patients 
with different types of solid tumor has been evaluated. Four 
fixed doses have been used 130, 200, 230, and 260 mg/m2. 
The regimens were well tolerated by the patients.
This study is limited by the fact that the sample size was 
small, and the blood samples were difficult to collect at 
the post infusion period; however, we were able to collect 
blood samples at 0, 1, and 3rd h for 23 patients and post 
infusion samples for five patients at 5th hour and 13th hour.
CONCLUSION
Clinical pharmacokinetics is the application of 
pharmacokinetic principles to the safe and effective 
therapeutic management of drugs in an individual patient. 
Primary goals of clinical pharmacokinetics include 
enhancing efficacy and decreasing toxicity of a patient’s 
drug therapy. The development of strong correlations 
between drug concentrations and their pharmacologic 
responses has enabled clinicians to apply pharmacokinetic 
principles to actual patient situations. To administer drugs 
optimally we need the knowledge of mechanism of drug 
absorption and also its kinetics.
In this study, paclitaxel has shown nonlinear 
pharmacokinetics, but the peak plasma concentrations did 
not increase with the dose. Further studies are required to 
correlate serious toxic symptoms such as myelosuppression 
with dose intensity.
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